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http://dx.doi.org/10.1016/j.jacl.2014.03BACKGROUND: Glucose, the conventional osmotic agent in peritoneal dialysis (PD) solutions, may
contribute to atherogenic dyslipoproteinemia and increased cardiovascular risk.
OBJECTIVE: To determine whether a low-glucose PD regimen may improve the serum lipid and
lipoprotein profile in patients with diabetes.
METHODS: A prospective, open-label, parallel group, multinational, randomized, controlled trial
with a 6-month follow-up, comprising 251 patients with diabetes receiving PD. Patients were random-
ized to a low-glucose PD regimen (dextrose-based PD solution plus icodextrin, a starch polymer, and
amino acids) or a conventional PD regimen (dextrose PD solutions). Serum lipid and apolipoprotein
profiles were determined at baseline and 3 and 6 months.
RESULTS: Serum triglycerides, very low-density-lipoprotein cholesterol, and apolipoprotein
B (apoB) decreased significantly in the intervention group at both 3 and 6months compared with baseline
(serum triglycerides: median change at 3 months 20.5 mmol/L, P , .001, at 6 months 20.3 mmol/L,
P , .001; very low-density-lipoprotein cholesterol: 20.3 mg/dL, P , .001; 20.3 mg/dL, P , .001;
and apoB:28.5 mg/dL, P, .001;23.6 mg/dL, P5 .043, respectively) and also compared with the con-
trol group. In contrast, apoB levels increased significantly in the control group at 3 and 6 months
compared with baseline (5.3 mg/dL, P5 .041; 5.2 mg/dL, P5 .007, respectively). Percentage of patients
on lipid-lowering medications at baseline and intensity of therapy was equivalent in each group. The
apoB decrease was not affected by lipid-lowering medications in the intervention group.
CONCLUSION: A low glucose-PD regimen significantly improved the atherogenic lipoprotein pheno-
type compared with PD patients treated with a conventional glucose regimen.
 2014 National Lipid Association. Open access under CC BY-NC-ND license.Patients on peritoneal dialysis (PD), particularly those
with diabetes,1 may have a greater risk of myocardial infarc-
tion2 and atherosclerotic death3 than those on hemodialysistmail.com
d for publication March 28, 2014.
sociation.
.007
Open access under CC BY-NC-ND(HD). In both PD and HD patients, hypertriglyceridemia
and low levels of high-density lipoprotein cholesterol
(HDL-C) are common. However, apolipoprotein B (apoB)
levels are higher in PD than in HD patients and characteris-
tically apoB is disproportionately elevated compared with
low-density lipoprotein cholesterol (LDL-C), pointing to license.
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particles.4 This raises the possibility that this atherogenic
dyslipoproteinemia5,6 might be responsible, at least in
part, for the increased coronary artery event rate in PD
compared with HD patients.
Glucose, used as an osmotic agent in PD, may contribute
to the pathogenesis of this atherogenic dyslipoproteinemia.
Depending on the glucose concentration and the membrane
transport status, PD patients can absorb up to 200 g of
glucose from the dialysis fluid per day.7,8 The increased
glucose load can increase hepatic fatty acid synthesis and
consequently increase hepatic triglyceride (TG) synthesis
and secretion9 resulting in increased very LDL (VLDL)
and LDL particle numbers.10–12 Because each VLDL and
LDL particle contains 1 molecule of apoB, plasma apoB
levels increase in parallel.
Accordingly, limiting the amount of glucose in the PD
prescription might improve the atherogenic lipoprotein
profile in PD patients, as suggested by previous work.14,15
IMPENDIA (Improved Metabolic control of Physioneal,
Extraneal, and Nutrineal [P-E-N] vs Dianeal-only treat-
ment in DIAbetic PD patients) and EDEN (Evaluation of
Dianeal, Extraneal, and Nutrineal [D-E-N] in diabetic
PD patients) were trials primarily designed to determine
if low-glucose dialysate (icodextrin, a starch polymer,
plus amino acids substituted for dextrose-based PD solu-
tions for part of the PD prescription) improved metabolic
status in diabetic patients treated with PD. Diabetic con-
trol, as estimated by HbA1c, was the primary end point.
These results have been reported and demonstrated sig-
nificant improvement.16 This analysis details the effect
of low-glucose PD on plasma lipid, lipoprotein, and apoli-
poprotein levels.Methods
The study design, methodology, and initial results of the
IMPENDIA and EDEN randomized, controlled trials have
been described previously.16 IMPENDIA (Clinicaltrials.gov
registration NCT00567398 Canada, Australia, andNewZea-
land; NCT00567489 in Europe and Asia) is a prospective,
open-label, parallel group, multinational randomized, con-
trolled trial, which determines whether a glucose-sparing
PD prescription would improve metabolic control in diabetic
PD patients compared with a glucose-only prescription
(Physioneal) over 6 months. The EDEN trial was a phase
III protocol performed in Colombia (NCT01219959). The
EDEN study is identical to IMPENDIA except that Dianeal
was substituted for the pH-neutral Physioneal because of
the unavailability of Physioneal solutions in Colombia.
Because Dianeal and Physioneal have identical glucose con-
centrations, the results of IMPENDIA and EDEN were com-
bined based on an a priori analytical plan. Study protocols
were approved by ethics committees at participating centers.
All patients provided written informed consent before
participation.Subjects were randomized to intervention (low-glucose
PD) or control (high-glucose PD) using a centralized
randomization scheme. The eligible study population
included incident and prevalent patients with type 1 and
type 2 diabetes, aged $18 years performing continuous
ambulatory PD or automated PD for $30 days. Eligibility
criteria included HbA1c level .6.0% and #12.0%, blood
hemoglobin concentration of $8.0 g/dL and #13.0 g/dL,
and total Kt/Vurea $1.7. Kt/Vurea is an arithmetic formula
expressing total urea clearance (K) per minutes per week
(t) adjusted to the patient’s urea volume of distribution
(Vurea). A value of .1.7 is considered adequate dialysis
by international standards. Patients entering the study
were expected to remain on PD for the study duration
period (at least 6 months). A full list of exclusion criteria
and study methodology detail is available online in the pri-
mary publication supplemental file.16
Lipids and apolipoproteins were assayed in serum
samples drawn at screening, baseline, 3-month (for the
majority of subjects), and 6-month end-of-study visits.
Total cholesterol (TC), LDL-C, HDL-C, and serum TG
were measured directly in serum. Very LDL cholesterol
(VLDL-C) was calculated as TC 2 LDL-C and HDL-C.
Apolipoproteins measured were: apolipoprotein (a) (Lp(a)),
apolipoprotein A1 (apoA1), and apoB.
Patients fasted and had no dwelling PD solution for
10 hours before blood samples were collected. Samples
were assayed at a central laboratory (Baxter’s Clinical
Laboratory Services, Round Lake, IL, USA) using validated
techniques. TC was determined using Trinder’s colorimetric
absorption spectrophotometry after enzymatic digestion
and oxidation. LDL-C and HDL-C levels were directly
measured in a similar fashion using a 2-reagent elimination/
catalase technique (Siemens Healthcare Diagnostics, Tarry-
town, NY, USA). TG levels were measured by colorimetric
absorption after a 3-step enzymatic reaction.
ApoA1 and apoB were measured by immunonephelom-
etry on a Siemens BN-ProSpec analyzer (Siemens Health-
care Diagnostics). Lp(a) was measured using polystyrene
particle-enhanced immunonephelometry and N-Latex-Lp(a)
Reagent.17–20
Medications were administered as determined by the
treating physician. This included both hypoglycemic and
hypolipidemic medications. Information regarding prescrip-
tion of any lipid-lowering medications, including statins,
fibrates, bile sequestration agents, and/or ezetimibe, was
specifically requested from patients at baseline and the 3- and
6-month visits. Changes in these medications in relation to
changes in lipid and apolipoprotein levels were identified and
evaluated. Changes in insulin or other hypoglycemic agents
during the trial were also determined.
Statistical methods
The statistical plan, which was developed before comple-
tion of either clinical trial or database lock, combined both
trials (IMPENDIA/EDEN) to achieve the desired sample
Table 2 Baseline lipid and apolipoprotein levels of
randomized study groups
Parameter*
Control
(Dextrose)
(n5 127)
Low Glucose
(P-E-N or D-E-N)
(n 5 124)
Total cholesterol, mmol/L 5.1 6 1.5 5.2 6 1.4
LDL-C, mmol/L 2.8 6 1.1 3.0 6 1.2
HDL-C, mmol/L 1.1 6 0.4 1.1 6 0.3
VLDL-C, mmol/L 1.3 6 1.4 1.1 6 0.9
TG, mmol/L† 2.1 (0.4–27.7) 1.9 (.6–15.0)
apoB, mg/dL 93.8 6 27.5 95.5 6 26.6
apoA1, mg/dL 133.7 6 25.8 135.4 6 25.4
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sures analysis of variance (RM-ANOVA) was performed
in the analysis to examine change in lipids/lipoproteins.
RM-ANOVA incorporated time (corresponding to visits
when the endpoint of interest was measured), treatment
group (Dianeal only vs P-E-N/D-E-N), and their interaction
(time ! treatment group) as primary independent class
variables.
The relationship between treatment groups and quartiles
of change in apoB from baseline was also analyzed. All
data were expressed as mean 6 standard deviation with
exception of TGs. Given the nonparametric distribution of
TGs, values were expressed as median with range.Lp(a), mg/dL 21.1 6 21.2 21.3 6 22.1
apoA1, apolipoprotein A1; apoB, apolipoprotein B; D-E-N, Dianeal,
Extraneal, and Nutrineal; HDL-C, high-density lipoprotein cholesterol;
LDL-C, low-density lipoprotein cholesterol; Lp(a), lipoprotein(a);
P-E-N, Physioneal, Extraneal, and Nutrineal; TG, triglyceride; VLDL-C,
very low-density lipoprotein cholesterol.
*Mean and standard deviation are shown for continuous variables
other than TG.
†Mean (range).Results
In total, 251 patients were randomized to either interven-
tion (n5 124) or control groups (n5 127). The baseline
characteristics of enrolled randomized patients are shown in
Table 1. Time on dialysis was similar between groups at
1.7 6 2.0 years in the control group and 1.5 6 1.8 years in
the intervention group. Baseline values of all lipids, lipopro-
tein lipids, and apolipoproteins are shown in Table 2. Base-
line levels of VLDL-C and lipoprotein levels were not
obtained in a few patients from both control and intervention
arms. Lipid and apoB measurements were performed in 110
control and 91 intervention patients at 3 months, and 120
control and 106 intervention patients at 6 months. One
patient in the intervention arm had lipid level measurements
without accompanying lipoprotein level measurements. No
significant differences were demonstrated between groups
at baseline, indicating balanced randomization.
Changes in lipids and apolipoproteins during the study
period are shown in Table 3. In the control group, there were
no statistically significant decreases in any measurements
during the study period. On the other hand, significant in-
creases from baseline in apoB levels were observed in theTable 1 Baseline demographics of randomized study group
Parameter*
Control
(Dextrose)
(n5 127)
Low Glucose
(P-E-N or D-E-N)
(n5 124)
Age, years 58 6 13 57 6 12
Female, % 46.5 51.6
BMI, kg/m2 27 6 5 27 6 4
Race, %
Asian 32.3 33.9
Caucasian 32.3 33.1
Hispanic 25.2 25.0
Other 10.2 8.0
Time on dialysis, years 1.7 6 2.0 1.5 6 1.8
BMI, body mass index; D-E-N, Dianeal, Extraneal, and Nutrineal;
P-E-N, Physioneal, Extraneal, and Nutrineal.
*Mean and standard deviation are shown for continuous variables.control group at both 3 and 6 months (5.3 6 24.2 mg/dL,
P 5 .041; 5.2 6 25.4 mg/dL, P 5 .007, respectively). In
the low-glucose group, there were significant decreases
from baseline at both 3- and 6-month follow-up assessments
in TG (median change 20.5 mmol/L [range: 12–2.7],
P , .001; 20.3 mmol/L [range: 13–3.8], P , .001);
VLDL-C (20.3 mg/dL 6 0.8, P .001; 20.3 mg/dL 6 0.9,
P , .001), and apoB (28.5 mg/dL 6 18.4, P , .001;
23.6 mg/dL 6 23.9, P 5 .043). In the low-glucose group,
TG, VLDL-C, and apoB were significantly lower compared
with values observed in the control group at both 3 and
6 months (Table 3).
There were no significant changes in LDL-C, HDL-C,
apoA1, or Lp(a) in either the intervention or control groups.
Mean differences6 95% confidence interval (CI) in change
in all lipids and apolipoproteins from baseline to both
3 months and the end of the study between the treatment
groups were calculated. This difference was significant,
favoring the low-glucose PD regimen, at both 3- and (as
shown in Fig. 1) 6-month intervals (D TG: 0.8 mmol/L [95%
CI: 0.4–0.3], P , .001; 0.7 mmol/L [95% CI 0.3–1.1],
P 5 .002; D VLDL-C: 0.4 mg/dL [95% CI: 0.2–0.6],
P , .001; 0.3 mg/dL [95% CI: 0.1–0.5], P 5 .003; D apoB:
11.4 mg/dL [95% CI: 3.6–19.2], P 5 .004; 8.4 mg/dL
[95% CI: 0.8–15.9], P 5 .030). We next examined whether
differences in lipid-lowering medications could have
accounted for these findings. Statins accounted for approxi-
mately 80% of the total lipid-lowering medications used.
There were no significant differences in administration of
statins (Fig. 2) or other lipid-lowering medications (data
not shown, but mirrors changes for statins in Fig. 2) during
the course of the study between the 2 groups. In the control
group, 39.4%, and in the intervention group, 36.3% of
patients were not on lipid-lowering medications at any
Table 3 Changes in lipid and lipoprotein levels during the course of study
Parameter* Baseline 3 months 6 months
Total cholesterol, mmol/L
Control 5.1 6 1.5 (127) 5.2 6 1.6 (110) 5.1 6 1.6 (120)
Low glucose 5.2 6 1.4 (124) 4.8 6 1.3 (91)
P 5 .10
4.8 6 1.3 (107)
P 5 .73
LDL-C, mmol/L
Control 2.8 6 1.1 (127) 2.9 6 1.3 (110) 2.9 6 1.3 (120)
Low glucose 3.0 6 1.2 (124) 2.7 6 1.1 (91)
P 5 .18
2.8 6 1.1 (107)
P 5 .59
HDL-C, mmol/L
Control 1.1 6 0.4 (127) 1.1 6 0.3 (110) 1.0 6 0.4 (120)
Low glucose 1.1 6 0.3 (124) 1.1 6 0.4 (91)
P 5 .20
1.1 6 0.3 (107)
P 5 .30
VLDL-C, mmol/L
Control 1.3 6 1.4 (126) 1.2 6 1.0 (110) 1.2 6 1.0 (120)
Low glucose 1.1 6 1.9 (124) 0.9 6 0.6 (91)
P , .001
0.9 6 0.5 (107)
P 5 .003
TG, mmol/L†
Control 2.1 (0.4–27.7) (127) 2.1 (0.6–13.2) (110) 2.0 (0.5–16.9) (120)
Low glucose 1.9 (0.6–15.0) (124) 1.8 (0.4–6.0) (91)
P , .001
1.7 (0.7–7.3) (107)
P 5 .002
apoB, mg/dL
Control 93.8 6 27.5 (119) 98.5 6 33.5 (110) 98.6 6 32.8 (120)
Low glucose 95.5 6 26.6 (120) 88.3 6 24.9 (91)
P 5 .004
90.2 6 28.4 (106)
P 5 .03
apoA1, mg/dL
Control 133.7 6 25.8 (119) 132.7 6 25.8 (110) 129.7 6 25.4 (120)
Low glucose 135.4 6 25.4 (120) 127.2 6 26.2 (91)
P 5 .10
125.0 6 26.0 (106)
P 5 .134
Lp(a), mg/dL
Control 21.1 6 21.2 (118) 22.4 6 24.0 (110) 26.5 6 28.5 (120)
Low glucose 21.3 6 22.1 (120) 25.2 6 24.7 (91)
P 5 .49
28.3 6 30.4 (106)
P 5 .56
apoA1, apolipoprotein A1; apoB, apolipoprotein B; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; Lp(a),
lipoprotein (a); TG, triglyceride; VLDL-C, very low-density lipoprotein cholesterol.
*Mean 6 standard deviation is shown for continuous variables, with the exception of TG.
†Median (range). Numbers of subjects are shown in parentheses. P values represent the comparison between the control and intervention groups at 3
and 6 months.
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lowering medications, 40.2% and 35.5% of control and
intervention patients, respectively, had no change in dose
during the study. Therefore lipid-lowering medications
were unlikely contributors to changes in lipid parameters.
An increase in lipid-lowering medications during the course
of study was recorded in 10.2% of control patients and 6.5%
of intervention patients; conversely, a decrease in lipid-
lowering medications was seen in 10.2% of control and
21.8% of intervention patients.
Further analyses were performed, restricted to patients
who either were not receiving any lipid-lowering medica-
tions during the study period or whose lipid-lowering
medication dose remained unchanged throughout the study
(79.6% and 71.8% of control and intervention patients,
respectively). ApoB either increased or changed minimally
in the control group (Fig. 3). In contrast, decreases in apoBlevels, similar in magnitude to those observed in the overall
group, occurred in the subset of patients in the intervention
group who were not receiving any lipid-lowering medica-
tions or whose dose of lipid-lowering medications did not
change. The magnitude of change from baseline quartile
of apoB was examined (Fig. 4). In the intervention group,
the greatest apoB reductions occurred in patients in the
highest baseline quartile of apoB in which mean apoB
levels were reduced by 21.1 mg/dL at 6 months vs baseline.
In contrast, apoB levels increased in most patients in the
control group during the study period, with the largest
changes occurring in those within the third baseline quartile
of apoB. Negligible changes were observed in the highest
baseline quartile of the control group.
Over the course of the trial, the HbA1c was 0.5% (95%
CI: 0.1-0.8; P 5 .006) lower in the intervention compared
with the control group. This decrease could not be explained
Figure 1 Difference in mean change from baseline between
control and low-glucose groups at the 6-month visit. ApoA1,
apolipoprotein A1; apoB, apolipoprotein B; HDL-C, high-density
lipoprotein cholesterol; LDL-C, low-density lipoprotein choles-
terol; Lp(a), lipoprotein (a); Total-C, total cholesterol; TG, triglyc-
eride; VLDL-C, very low-density lipoprotein cholesterol.
*P 5 .030; **P 5 .003; ***P 5 .002.
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cemic agents between the 2 groups.Discussion
This study compares plasma-lipid and apolipoprotein
profiles in diabetic PD patients treated with glucose-sparing
dialysate with those receiving conventional glucose-based
dialysate. Plasma TG, VLDL-C, and plasma apoB all
decreased significantly in the glucose-sparing arm. By
contrast, there were no significant differences in the other
lipoprotein markers—TC, LDL-C, HDL-C, Lp(a), and
apoA1—in either group during the course of study.
We examined in detail whether the differences observed
could be due to differences in the use of lipid-lowering
medication therapy between the 2 groups. There was no
evidence that this was the case. The pattern of use, doses,
and changes in doses of lipid-lowering medications were
similar in both groups. Moreover, the same pattern and
extent of change in lipoprotein indices were evident in
patients not taking lipid-lowering medications or in whom
no change in dose occurred during the course of study.
Additionally, the observation that apoB levels in the highestFigure 2 Statin use during the course of the study. White
bars, control; black bars, low glucose.baseline apoB quartile of the control group changed
minimally suggests that substantial decreases seen in the
intervention group in response to glucose-sparing dialysate
did not simply reflect regression to the mean. Accordingly,
it seems reasonable to conclude that the changes docu-
mented were the consequences of the low-glucose PD
regimen.
The pattern of change seen here is likely related to the
reduced mass of glucose absorbed from the dialysate and
delivered to the liver. That the HbA1c was significantly
lower without significant difference between the groups in
terms of insulin or hypoglycemic agents is evidence in
favor of this conclusion. Dialysate glucose, which is de-
signed to be an osmole for ultrafiltration (fluid removal),
unfortunately is itself absorbed across the peritoneal cavity
and so constitutes a metabolic load. The extent of this load
depends on the overall amount of glucose administered and
the membrane transport capacity for glucose.7,8,21 Glucose
absorbed and delivered to the liver stimulates hepatic
fatty acid synthesis and therefore triglyceride synthesis
and secretion. Increased VLDL apoB secretion and LDL
apoB production therefore ensues.9–12 In addition, excess
glucose loading can provoke insulin resistance, which
can also contribute to increased hepatic lipid synthesis
and VLDL secretion.22 Hypertriglyceridemia also stoichio-
metrically accelerates cholesterol ester transfer protein–
mediated exchange of the 2 core lipids—cholesterol ester
and TG—between LDL and VLDL particles. This creates
greater numbers of LDL particles that are relatively TG-
enriched and cholesterol ester–depleted. TG in these parti-
cles is hydrolyzed by hepatic lipase producing the smaller,
denser, cholesterol-depleted particles characteristic of
hypertriglyceridemia.23
The combination of increased plasma TG, VLDL-C, and
apoB, but unchanged LDL-C in the PD patients is consistent
with the metabolic consequences of increased glucose
delivery to the liver. It follows that reduction of glucose
delivery in PD might improve these abnormalities. Specif-
ically, reduced VLDL secretion would lead to lower TG,
VLDL-C, and apoB. Lower TG will reduce cholesterol ester
transfer protein–mediated core lipid exchange and, there-
fore, the cholesterol mass per LDL particle will not be
reduced. Accordingly, the observation that LDL-C did not
change although apoB decreased is exactly what would be
predicted to happen. An alternative and perhaps comple-
mentary explanation for the decrease in apoB is that the
increased amino acid content of dialysate in the low-glucose
PD regimen may itself be beneficial, because in vitro studies
have demonstrated that increased delivery of amino acids
can reduce apoB secretion by HepG2 cells.24
Whether apoB is a bettermarker of cardiovascular risk than
cholesterol indices has been controversial.13,25 However, a
series of recent studies based on discordance analysis have
consistently shown that apoB and LDL particle number
are more closely associated with cardiovascular risk than
LDL-C and non-HDL-C.26–29 Moreover, there is no dispute
that higher levels of apoB are associated with greater
Figure 3 Change in apolipoprotein B in patients (A) not prescribed lipid-lowering medications (P 5 .023 at 3 months and P 5 .010 at
6 months) or (B) without a change in dose of lipid-lowering medication (P 5 .25 at 3 months and P 5 .24 at 6 months) during the course of
the study. apoB, apolipoprotein (B); black bars, low glucose; white bars, control.
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Therefore, the reductions in apoB documented in this study
reflect metabolic improvement. Of interest, the average
apoB of 93–95 mg/dL in PD patients before glucose-sparing
dialysis therapy corresponds to the 55th percentile of the
American population,30 a level that is well above a target level
of 80mg/dL for apoB as identified by the recent Canadian and
European Guidelines.31,32 Based on our meta-analysis of the
prospective association of apoB with cardiovascular risk, a
reduction of 8.4 mg/dL in apoB in the general population
would result in an 8.1% reduction in cardiovascular events.13
The greatest decreases in apoB, approximately 20mg/dL from
baseline, which were observed in the group with the highest
baseline levels, would be predicted to reduce cardiovascular
events by approximately 19%.13 Obviously, predictions based
on a general population cannot be extrapolated to a particular
group such as PD patients. However, a directionally beneficial
change in levels of apoB, particularly observed in diabetics,
the subgroup in whom an excess cardiovascular risk with
PD has been identified,1 is a promising finding.Figure 4 Mean change in apolipoprotein B at 3 months and
6 months according to the baseline quartile. Shading shows
quartiles of apoB range. apoB, apolipoprotein (B); white, Q1
and Q2 (39–,89 mg/dL); gray, Q3 (89–,110 mg/dL); black,
Q4 (110–182 mg/dL).A limitation of our study was that total daily-prescribed
glucose was not monitored. Systemic underprescribing
of glucose-based PD solutions in the intervention arm or
overprescribing in the control arm could have occurred.
Irrespective of this possibility, demonstration of the princi-
ple that attenuating the glucose content of the PD prescrip-
tion has salutary effects on the lipid profile is shown. As
well, because of local licensing issues, the control dialysates
were not the same in the IMPENDIA and EDEN arms.
However, the glucose concentrations were identical in both
these studies, and both data sets exhibited the same trends
with the same extent of change in all parameters.
In summary, a glucose-sparing dialysis regimen resulted
in a less atherogenic lipoprotein profile as evidenced by
decreases in plasma TG, VLDL-C, and apoB, a result that
is consistent with the known adverse effects of glucose on
apoB lipoprotein metabolism. This randomized controlled
study demonstrates that the composition of fluid instilled in
the peritoneal cavity can have significant effects on
metabolic indices. This finding may have important impli-
cations for minimizing cardiovascular risk in PD patients.Acknowledgments
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